A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  • End date
    Mar 20, 2022
  • participants needed
  • sponsor
Updated on 26 October 2020
AbbVie_Call Center
Primary Contact
Macquarie University /ID# 211951 (0.9 mi away) Contact
+752 other location


This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission in order to identify the induction dose of upadacitinib for further evaluation in sub-study 2. The objective of sub-study 2 is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of sub-study 3 is to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.

Treatment Placebo, ABT-494, Updacitinib (ABT-494)
Clinical Study IdentifierNCT02819635
Last Modified on26 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age between 16 yrs and 75 yrs?
Gender: Male or Female
Do you have any of these conditions: Ulcerative Colitis or Ulcerative Colitis (Pediatric)?
Note: Adolescent participants at the age of 16 or 17 years old will be
eligible to participate if approved by the country or regulatory/health
authority. If approval has not been granted, only participants >= 18 years old
will be enrolled
Adolescents must weigh >= 40 kilograms and meet the definition of Tanner Stage
at Screening Visit
Diagnosis of ulcerative colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available
Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points and endoscopic sub score of 2 to 3 (confirmed by central reader)
Demonstrated an inadequate response to, loss of response to, or intolerance to at least one of the following treatments including: oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies in the opinion of the investigator
Note: Participants who have had inadequate response, loss of response to
conventional therapy, but have not failed biologic therapy (Non-bio-IR) and
have received a prior biologic for up to 1 year may be enrolled, however they
must have discontinued the biologic for reasons other than inadequate response
or intolerance (e.g., change of insurance, well controlled disease) and must
meet criteria for inadequate response, loss of response or intolerance to
aminosalicylates, corticosteroids, and/or immunosuppressants as defined above
If female, participant must meet the criteria for Contraception Recommendations
Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit prior to study drug dosing

Exclusion Criteria

Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC)
Current diagnosis of fulminant colitis and/or toxic megacolon
Participant with disease limited to the rectum (ulcerative proctitis) during the Screening endoscopy
Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline
Participant on azathioprine or 6-mercaptopurine within 10 days of baseline
Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period
Participant with previous exposure to Janus Activated Kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib)
Screening laboratory and other analyses show any abnormal results
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet